University Hospitals (UH), the largest health system university in northeastern Ohio, today jointly released Masimo SafetyNet™, an economically scalable and innovative patient management system designed to help clinicians treat patients remotely.
This telemedicine solution combines the ground-breaking Masimo SET® mobile and low-perfusion measurement™ technology-driven wireless Radius PPG™ pulse oximeter with Doctella™, which is a safe, remote patient monitoring platform at home , Can be accessed from the patient’s iOS or Android smartphone or smart device.
The COVID-19 health emergencies have significantly increased the demand for remote monitoring and patient communication solutions from various agencies. To actively prepare for the surge of COVID-19 patients while ensuring the safety of other patients and medical staff, the new solution allows UH and other hospitals to extend patient monitoring to other facilities in their homes or temporarily set up to take into account the increasing demand. The current WHO guidelines recommend monitoring blood oxygen saturation (SpO 2 ), respiration rate (RR), and body temperature in patients with suspected or confirmed COVID-19. Masimo and UH use existing technology to provide a safe remote solution to meet this 1. Increasing demand.
Masimo SafetyNet provides the healthcare team with a single platform solution that combines the cloud-based safety monitoring platform with the clinically proven SET ® pulse oximeter, which is estimated to be used by more than 200 million patients per year1. In addition to SpO 2, Radius PPG can continuously monitor pulse rate (PR), perfusion index, PVi ® and RRp ®, and respiration rate through a photoelectric plethysmograph.
Patients can be sent home, and single cases of multi-day supply can use Radius PPG sensors. Patients can access the Doctella mobile app through a family medical care package, which is called CareProgram, and the COVID-19 expert guide Consistent, patients can use it easily and intuitively. Radius PPG uses secure Bluetooth ® wireless technology to share its SpO 2, PR and RRp data with Doctella. In addition, Doctella can also manually collect other physiological data, such as body temperature. Doctella CareProgram reminds patients to answer questions twice a day or as directed by doctors, such as “Do you have difficulty breathing?” and “What is your temperature?”, and broadcast the above answers and physiological monitoring data to clinic staff in the hospital Evaluation. The Doctella Clinician Portal makes it easy for medical staff to track patient compliance, help them determine when intervention may be needed, and provide insights to help medical staff prioritize patients. CarePrograms can be fully customized to suit each institution’s procedures, each patient’s needs, and any changes to the COVID-19 guidelines, and even after deployment, they can be updated by the supplier through the cloud to obtain the maximum flexibility.
Peter Pronovost, MD, UH Clinical Transformation Chief, explained: “We appreciate Masimo’s immediate cooperation to establish this innovative platform, which will greatly assist us in upgrading remote monitoring and meeting patient healthcare needs, while addressing capacity and safety issues. For For patients with congestive heart failure or chronic obstructive pulmonary disease (COPD), we can provide them with this remote monitoring function so that they do not face the risk of COVID-19 infection because they are close to patients who may be infected. Similarly, for COVID -19Diagnosed patients, we can properly isolate them from other patients, and at the same time ensure that they can get first-class medical care for their health during the rehabilitation process.”
Joe Kiani, founder and CEO of Masimo, said: “We thank the brave nurses and doctors who took care of us all in the hospital during this pandemic. We are very happy to help them divert through Masimo SafetyNet and do their best to effectively care for COVID- 19 patients. I am very happy to work with UH to introduce this technology into the healthcare industry and help them meet the challenges of this unprecedented period.”
Daniel I. Simon, MD, UH Clinical and Scientific Director and Dean of UH Cleveland Medical Center, said: “The alliance demonstrates UH’s strategy to promote people’s health. By deploying the “outside to inside” strategy and working with Masimo Establishing this partnership will enable our patients to obtain the most advanced treatments while we help future users and the industry transform and improve products.”
UH plans to start testing the system next week.
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide variety of industry-leading monitoring technologies, including innovative measurement equipment, sensors, patient monitors, automation and interoperability solutions. Our mission is to improve patient medical outcomes and reduce treatment costs. In 1995, the company launched the Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximeter. More than 100 independent and objective studies have shown that its performance is superior to other pulse oximeters. Technology 2. Studies have shown that Masimo SET ® helps clinicians reduce severe retinopathy in premature neonates3, improve CCHD screening in neonates4, and can reduce rapid response to team mobilization when used in continuous monitoring of Masimo Patient SafetyNet™ in postoperative wards , ICU transshipment and cost 5-7. Masimo SET ® is estimated to have been used in more than 200 million patients in leading hospitals and other medical institutions around the world1, and is 9 of the top 10 hospitals in the honor list of the best hospitals in 2019-2020 by the US News and World Report The main pulse oximeter 8 used. Masimo is constantly optimizing SET®. In 2018, it was announced that the accuracy of SpO 2 on the RD SET® sensor in mobile state has been significantly improved, making clinicians more confident that the SpO 2 value they rely on accurately reflects the patient’s physiology. status. In 2005, Masimo launched rainbow ® pulse carbon oxygen-oxygen saturation meter technology, which achieved non-invasive continuous monitoring of blood components that could only be invasively measured in the past, including total hemoglobin (SpHb ® ), oxygen content (SpOC™), Carbon oxyhemoglobin (SpCO ® ), methemoglobin (SpMet ® ), pulse perfusion variability index (PVi ® ), RPVi™ (rainbow ® PVi), oxygen reserve index (ORi™). In 2013, Masimo launched the Root ® patient monitoring and interoperability platform, which was designed from the ground up to be as flexible and extensible as possible to add other Masimo and third-party monitoring technologies. Key Masimo additions include the next-generation SedLine ® brain function monitor, O3 ® local oximeter, and ISA™ CO2 analyzer with NomoLine ® sampling cable. Masimo’s continuous and spot monitor pulse oximeter-oxygen saturator® family includes devices designed for use in a variety of clinical and non-clinical settings, including wireless wearable technologies (such as Radius-7® and Radius PPG™) , Portable devices (such as Rad-67™), fingertip pulse oximeters (such as MightySat ® Rx), hospital and home dual-use devices (such as Rad-97 ®). Masimo’s in-hospital automation and interoperability solutions are centered on the Iris® platform, including Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™. For Masimo and
The University Hospital was established in 1866 to meet the needs of patients through an integrated network of 18 hospitals, more than 50 health centers and outpatient facilities, and 200 physician clinics across 16 counties in northern Ohio. The flagship academic medical center of the system is the Cleveland Medical Center, a university hospital located in the Cleveland University Circle, affiliated with Case Western Reserve University University School of Medicine. The main campus also includes University Hospital Rainbow Babies and Children’s Hospital (among the top children’s hospitals in the U.S.); University Hospital MacDonald Women’s Hospital (the only women’s hospital in Ohio); University Hospital Harrington Cardiovascular Research Institute (a complex of cardiovascular surgery) High-traffic national referral center); and University Hospital Seidman Cancer Center (part of the NCI-designated case comprehensive cancer center). UH is home to some of the most prestigious clinical and research programs in the United States, including cancer, pediatrics, women’s health, orthopedics, radiology, neuroscience, cardiac internal medicine and cardiovascular surgery, digestive health, transplantation, and urology. UH Cleveland Medical Center has performed best in various ranking surveys throughout the United States, including “Best Hospital in the United States” by “U.S. News and World Report”. UH is also home to the Harrington Discovery Institute of the University Hospital, which is part of the Harrington Discovery and Development Project. UH is one of the largest employers in northeastern Ohio, with 28,000 doctors and employees. Promoting health sciences and the art of compassion is UH’s vision to benefit patients and enjoy the future. The firm’s mission is to heal, teach and discover.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include various statements regarding the potential efficacy of Masimo SafetyNet™, Radius PPG™, Doctella™, SET ® and RRp ®, etc. These forward-looking statements are based on current expectations of future events affecting us and are subject to risks and uncertainties. All risks and uncertainties are difficult to predict, most of which are beyond our control and may lead to our actual results The results expressed in our forward-looking statements are very different and diametrically opposed, due to various risk factors, including but not limited to risks related to: our assumptions about the repeatability of clinical results; our unique Masimo The belief of noninvasive measurement technologies (including Masimo SafetyNet, Radius PPG, Doctella, SET ® and RRp) that these technologies can contribute to positive clinical results and patient safety; and we believe that Masimo noninvasive medical breakthroughs can provide cost-effectiveness The risks associated with the solution and the belief in unique advantages; the risks associated with COVID-19; and other factors discussed in the “Risk Factors” section of our latest report to the US Securities and Exchange Commission (SEC), which can be found from The SEC website is freely available. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct in the future. All forward-looking statements contained in this press release are fully consistent with the aforementioned cautionary statements. We would like to remind you not to make inappropriate reliance on these forward-looking statements, these statements are only applicable today. Except as may be required by applicable securities laws, we have no responsibility to update, revise or clarify these statements or the “risk factors” contained in our latest report to the SEC, whether as a result of new information or future events It is also the result of other matters.
Disclaimer: The original version of this announcement is the officially authorized version. The translation is for convenience only. Please refer to the original text. The original version is the only legally effective version.
Solemnly declare: The copyright of this article belongs to the original author. The reprinted article is only for the purpose of spreading more information. If the author’s information is marked incorrectly, please contact us to modify or delete it immediately. Thank you.